Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised price targets for Meta, IREN, Coinbase, Roblox and others; IREN and Coinbase were upgraded, while other ratings held steady.
Stocks · News reference
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent BiologicsTransaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-08-28 AccNo: 0001193125-26-374788 Size: 148 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
-SEC Filing